These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Valacyclovir study stopped -- worse survival. James JS AIDS Treat News; 1995 Feb; (no 217):7-8. PubMed ID: 11362306 [TBL] [Abstract][Full Text] [Related]
66. DHPG (Gancyclovir) improves survival in CMV pneumonia. Mai M; Nery J; Sutker W; Husberg B; Klintmalm G; Gonwa T Transplant Proc; 1989 Feb; 21(1 Pt 2):2263-5. PubMed ID: 2540565 [No Abstract] [Full Text] [Related]
67. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Green M; Kaufmann M; Wilson J; Reyes J Clin Infect Dis; 1997 Dec; 25(6):1344-9. PubMed ID: 9431375 [TBL] [Abstract][Full Text] [Related]
68. Ganciclovir for severe cytomegalovirus infection in transplant recipients. Nicholson ML; Flower AJ; Simpson A; Donnelly PK; Veitch PS; Bell PR Lancet; 1988 Dec 24-31; 2(8626-8627):1501-2. PubMed ID: 2904627 [No Abstract] [Full Text] [Related]
70. Low-dose valacyclovir use with preemptive monitoring in kidney transplant recipients with intermediate cytomegalovirus infection risk. Velioğlu A; Alagöz S; Barutçu DA; Arıkan H; Aşıcıoğlu E; Aksu B; Seyahi N; Tuğlular S Turk J Med Sci; 2022 Aug; 52(4):1404-1407. PubMed ID: 36326374 [No Abstract] [Full Text] [Related]
71. Massive cytomegalovirus pneumonia and myocarditis in a renal transplant recipient: successful treatment with DHPG. Shabtai M; Luft B; Waltzer WC; Anaise D; Rapaport FT Transplant Proc; 1988 Jun; 20(3):562-3. PubMed ID: 2837853 [No Abstract] [Full Text] [Related]
72. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation. Leone F; Akl A; Giral M; Dantal J; Blancho G; Soulillou JP; Cantarovich D Transpl Int; 2010 Sep; 23(9):897-906. PubMed ID: 20230540 [TBL] [Abstract][Full Text] [Related]
73. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
74. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210 [TBL] [Abstract][Full Text] [Related]
75. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989 [TBL] [Abstract][Full Text] [Related]
76. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kielberger L; Bouda M; Jindra P; Reischig T Kidney Blood Press Res; 2012; 35(6):407-16. PubMed ID: 22584353 [TBL] [Abstract][Full Text] [Related]
77. Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir. MacDonald AS; Belitsky P; Cohen A; Lee S Transplant Proc; 1991 Feb; 23(1 Pt 2):1355-6. PubMed ID: 1846463 [No Abstract] [Full Text] [Related]
78. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113 [TBL] [Abstract][Full Text] [Related]